SABSW
SAB Biotherapeutics, Inc. NASDAQ$0.02
Mkt Cap $926,236
52w Low $0.02
-0.3% of range
52w High $0.05
50d MA $0.03
200d MA $0.03
P/E (TTM)
0.1x
EV/EBITDA
4.1x
P/B
0.0x
Debt/Equity
0.0x
ROE
8.8%
P/FCF
-1.6x
RSI (14)
—
ATR (14)
—
Beta
0.61
50d MA
$0.03
200d MA
$0.03
Avg Volume
22.7K
About
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South D…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.21 | -0.27 | -26.3% | 0.03 | -4.1% | +12.6% | +30.8% | +15.1% | +12.6% | +2.5% | -16.2% | — |
| Nov 13, 2025 | AMC | -0.46 | 0.58 | +227.4% | 0.03 | -19.3% | -3.0% | -9.6% | -26.8% | -11.7% | -11.7% | -25.3% | — |
| Aug 13, 2025 | AMC | -0.80 | -1.09 | -36.7% | 0.03 | -0.4% | -0.4% | -0.7% | +0.0% | -4.2% | -11.3% | +1.8% | — |
| May 9, 2025 | AMC | — | -0.56 | — | 0.03 | -0.3% | -12.6% | -22.4% | -20.6% | -23.1% | -22.7% | -17.1% | — |
| Sep 30, 2023 | AMC | — | -0.10 | — | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.14 | — | 0.10 | -18.6% | -18.6% | +9.7% | +5.4% | +36.0% | +20.5% | +13.8% | — |
| Mar 31, 2023 | AMC | — | -0.15 | — | — | — | — | — | — | — | — | — | — |
| Dec 31, 2022 | AMC | — | -0.18 | — | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.14 | $0.12 | -14.3% | +7.1% | -7.1% | +3.9% | -20.0% | -28.6% |
| Jun 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.14 | $0.14 | +0.0% | +0.0% | +0.0% | +7.1% | -7.1% | +3.9% |
| Jun 14 | Chardan Capital | Maintains | Buy → Buy | — | $0.14 | $0.14 | +0.0% | +0.0% | +0.0% | +0.0% | +7.1% | -7.1% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.16 | $0.13 | -17.5% | -39.9% | -37.6% | -31.4% | -31.4% | -12.5% |
| Aug 10 | Chardan Capital | Maintains | Buy → Buy | — | $0.19 | $0.19 | -0.1% | -2.3% | -26.3% | -36.7% | -30.4% | -30.4% |
| May 12 | Chardan Capital | Maintains | Buy → Buy | — | $0.21 | $0.31 | +47.6% | +19.0% | +14.2% | -5.5% | -9.5% | -23.2% |
| Mar 31 | Chardan Capital | Maintains | Buy → Buy | — | $0.38 | $0.36 | -6.3% | +26.8% | +8.9% | +0.1% | -9.8% | -9.8% |
| Nov 5 | Chardan Capital | Maintains | Buy → Buy | — | $1.65 | $1.87 | +13.3% | -0.6% | -0.6% | +14.5% | +9.1% | +11.5% |
| Nov 2 | Baird | Maintains | Outperform → Outperform | — | $1.21 | $2.18 | +80.2% | +44.6% | +43.8% | +36.4% | +35.5% | +35.5% |
Data updated apr 28, 2026 8:17pm
· Source: massive.com